Inositol Supplement Improves Clinical Pregnancy Rate in Infertile Women Undergoing Ovulation Induction for ICSI or IVF-ET

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2017 Dec 17

PMID 29245250

Citations 20

Authors

Xiangqin Zheng

Danmei Lin

Yulong Zhang

Yuan Lin

Jianrong Song

Suyu Li

Yan Sun

Affiliations

Soon will be listed here.

Abstract

Objective: Pretreatment of myoinositol is a very new method that was evaluated in multiple small studies to manage poor ovarian response in assisted reproduction. This study was to determine the efficacy of myoinositol supplement in infertile women undergoing ovulation induction for intracytoplasmic sperm injection (ICSI) or in vitro fertilization embryo transfer (IVF-ET).

Methods: A meta-analysis and systematic review of published articles evaluating the efficacy of myo-inositol in patients undergoing ovulation induction for ICSI or IVF-ET was performed.

Results: Seven trials with 935 women were included. Myoinositol supplement was associated with significantly improved clinical pregnancy rate [95% confidence interval (CI), 1.04-1.96; P = .03] and abortion rate (95% CI, 0.08-0.50; P = .0006). Meanwhile, Grade 1 embryos proportion (95% CI, 1.10-2.74; P = .02), germinal vescicle and degenerated oocytes retrieved (95% CI, 0.11-0.86; P = .02), and total amount of ovulation drugs (95% CI, -591.69 to -210.39; P = .001) were also improved in favor of myo-inositol. There were no significant difference in total oocytes retrieved, MII stage oocytes retrieved, stimulation days, and E2 peak level.

Conclusions: Myoinositol supplement increase clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. It may improve the quality of embryos, and reduce the unsuitable oocytes and required amount of stimulation drugs.

Citing Articles

The Clinical Use of Myo-Inositol in IVF-ET: A Position Statement from the Experts Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS), the Polish Society of Andrology, and the International Scientific Association for the Support....

Wdowiak A, Bakalczuk S, Filip M, Lagana A, Unfer V J Clin Med. 2025; 14(2).

PMID: 39860564 PMC: 11766415. DOI: 10.3390/jcm14020558.

Improvement in biochemical manifestations of the serum and follicular fluid and ICSI outcomes in PCOS patients with myo-inositol administration: prospective randomized research.

Yazdanpanah Z, Cheraghi E, Heydari Nasrabadi M, Salehipour M Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39718613 DOI: 10.1007/s00210-024-03745-w.

Myo-Inositol and Its Derivatives: Their Roles in the Challenges of Infertility.

Placidi M, Casoli G, Tatone C, Emidio G, Bevilacqua A Biology (Basel). 2024; 13(11).

PMID: 39596891 PMC: 11592302. DOI: 10.3390/biology13110936.

Treatment With a Patented 3.6:1 Myo-Inositol to D-chiro-Inositol Ratio, Antioxidants, Vitamins and Minerals Food Supplement in Women With a History of Assisted Reproductive Technique (ART) Failures: A Series of Case Reports.

Armijo-Sanchez A, Benitez Castillo N, Garcia-Vidal E, Luna Chadid M, Salvador Ballada C, Valls Ricart G Clin Med Insights Case Rep. 2024; 17:11795476241242265.

PMID: 38559382 PMC: 10981332. DOI: 10.1177/11795476241242265.

Diagnosis and management of infertility: NICE-adapted guidelines from the Italian Society of Human Reproduction.

Palomba S, Vigano P, Chamayou S, Donarelli Z, Costantini M, Marci R Reprod Biol Endocrinol. 2024; 22(1):9.

PMID: 38183116 PMC: 10768082. DOI: 10.1186/s12958-023-01179-2.

References

Zacche M, Caputo L, Filippis S, Zacche G, Dindelli M, Ferrari A . Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol. 2009; 25(8):508-13. DOI: 10.1080/09513590903015544. View

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S . Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci. 2011; 15(4):452-7. View

Tamura H, Nakamura Y, Korkmaz A, Manchester L, Tan D, Sugino N . Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril. 2008; 92(1):328-43. DOI: 10.1016/j.fertnstert.2008.05.016. View

Chiu T, Tam P . A correlation of the outcome of clinical in vitro fertilization with the inositol content and embryotrophic properties of human serum. J Assist Reprod Genet. 1992; 9(6):524-30. DOI: 10.1007/BF01204248. View

Pacchiarotti A, Carlomagno G, Antonini G, Pacchiarotti A . Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol Endocrinol. 2015; 32(1):69-73. DOI: 10.3109/09513590.2015.1101444. View

Papaleo E, Unfer V, Baillargeon J, Fusi F, Occhi F, De Santis L . RETRACTED: Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril. 2008; 91(5):1750-1754. DOI: 10.1016/j.fertnstert.2008.01.088. View

Granata R, Settanni F, Biancone L, Trovato L, Nano R, Bertuzzi F . Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: involvement of 3',5'-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl.... Endocrinology. 2006; 148(2):512-29. DOI: 10.1210/en.2006-0266. View

Azziz R, Ehrmann D, Legro R, Whitcomb R, Hanley R, Fereshetian A . Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001; 86(4):1626-32. DOI: 10.1210/jcem.86.4.7375. View

10.

van Loendersloot L, van Wely M, Limpens J, Bossuyt P, Repping S, van der Veen F . Predictive factors in in vitro fertilization (IVF): a systematic review and meta-analysis. Hum Reprod Update. 2010; 16(6):577-89. DOI: 10.1093/humupd/dmq015. View

11.

Ciotta L, Stracquadanio M, Pagano I, Carbonaro A, Palumbo M, Gulino F . Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci. 2011; 15(5):509-14. View

12.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

13.

Elter K, Imir G, Durmusoglu F . Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod. 2002; 17(7):1729-37. DOI: 10.1093/humrep/17.7.1729. View

14.

Nyboe Andersen A, Witjes H, Gordon K, Mannaerts B . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment. Hum Reprod. 2011; 26(12):3413-23. DOI: 10.1093/humrep/der318. View

15.

Buckett W . A review and meta-analysis of prospective trials comparing different catheters used for embryo transfer. Fertil Steril. 2006; 85(3):728-34. DOI: 10.1016/j.fertnstert.2005.08.031. View

16.

Papaleo E, Unfer V, Baillargeon J, Chiu T . Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol. 2009; 147(2):120-3. DOI: 10.1016/j.ejogrb.2009.09.008. View

17.

Unfer V, Carlomagno G, Dante G, Facchinetti F . Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012; 28(7):509-15. DOI: 10.3109/09513590.2011.650660. View

18.

Brusco G, Mariani M . Inositol: effects on oocyte quality in patients undergoing ICSI. An open study. Eur Rev Med Pharmacol Sci. 2013; 17(22):3095-102. View

19.

Colazingari S, Treglia M, Najjar R, Bevilacqua A . The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013; 288(6):1405-11. DOI: 10.1007/s00404-013-2855-3. View

20.

Tang T, Lord J, Norman R, Yasmin E, Balen A . Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012; (5):CD003053. DOI: 10.1002/14651858.CD003053.pub5. View